

PROGRAMME (ICRT-2009)



PROGRAMME

INTERNATIONAL CONFERENCE ON RADIOPHARMACEUTICAL THERAPY (ICRT-2009)

CARTAGENA, COLOMBIA, 3-7 NOVEMBER 2009

THE POSTERS WILL BE ON DISPLAY ON ALL DAYS. THE PARTICIPANTS ARE REQUESTED TO FIX THEIR POSTERS ON 3RD NOVEMBER AND REMOVE THEM ON 7th NOVEMBER 2009

Tuesday: 3 November 2009

Whole Day	Participants start arriving
0900-2100	Registration
2000-2100	Executive Council Meeting of WRPTC

1900-2300 Informal get-together and Dinner: Hilton Hotel Restaurant

Wednesday: 4 November 2009

0800-1600 Registration continues

**0800-1015 Abstract No Scientific Session-1
Opening & Thyroid I**
Chairpersons: Prof. JH Turner (Australia), Prof. A. Ellmann (South Africa)

0800-0815 Opening Remarks:
Dr. Patricia Bernal Trujillo, Chairman, Organizing Committee
Prof. Richard Baum, Chairman, Scientific Committee
Prof. Ajit Kumar Padhy, Chairman, WRPTC

0815-1015 Invited Lecture

0815-0845	1	Creativity and motivation: A Necessity for Advancing Research and Healthier Life	Prof. AH Elgazzar (Kuwait)
0845-0925	2	I-131 Therapy of Thyroid Cancer	Prof. Stanley Goldsmith (USA)
0925-0955	3	Equivalence randomised stratified control Trial in Remnant Ablation of DTC	Prof. C.S. Bal (India)
0955-1015	4	Thyroid antibodies and Differentiated Thyroid Cancer	Prof. J. Mihailovic (Serbia)

Proffered Presentations

Poster Presentations

(To be viewed and discussed during the coffee break at 1015-1100 hrs. TODAY (04/11/09))

5	Clinical experience with recombinant human thyrotrophin in the radioiodine treatment of patients with differentiated thyroid cancer on L-thyroxine	Dr. Zvezdana Rajkovaca (Bosnia and Herzegovina)
6	Use of recombinant TSH (r-TSH) stimulation for treatment of bone metastasis & follow-up in	Dr. Partha S Choudhury, et al (India)

	differentiated thyroid carcinoma : work in progress.	
7	The level of carcinogenic risk after radioiodine ablation for low risk group papillary thyroid cancer	Dr. Tatiana Hadjieva, et al (Bulgaria)
8	Effect of low dose radioiodine therapy in differentiated thyroid carcinoma	Dr. Farid Alam, et al. (Bangladesh)
9	Enhanced sensitivity of lesion detection by performing delayed I-131 whole body scanning beyond the standard 48 hr scan protocol in patients of metastatic differentiated thyroid cancer treated with rhTSH (Thyrogen) intervention	Dr. Kelvin Loke, et al (Singapore)
10	FRAX assessment of Osteoporotic fracture probability in patients of differentiated thyroid cancer on Thyroid hormone suppressive therapy	Dr. Butch Magsombol, Dr. Kelvin Loke, et al (Singapore)
11	Scintigraphic profile of thyroid diseases in Yaounde	Dr. Joseph Francis Nwatsok, et al (Cameroun)
12	Thyroid cancer imaging: Are we missing nodules with high resolution collimator and limiting pinholes studies to anterior view only?	Prof. AH Elgazzar, et al (Kuwait)
13	The influence of treatment of Subclinical Hyperthyroidism with radioiodine on achievement of euthyroid state, thyroid volume and level of Sex Hormone Binding Globulin.	Dr. Grzegorz Kaminski, et al (Poland)
14	Radioiodine therapy in childhood thyroid cancer	Dr. Abu-Taher Muhammad (Bangladesh)
15	The role of high resolution neck ultrasound in combination with thyroglobulin measurement in the wash-out fluid from the fine needle aspiration of neck lesions (FNAB-Tg) in patients with differentiated thyroid carcinoma and positive or negative Iodine-131 whole body scintigraphy.	Dr. S. Frangos, et al. (Cyprus)
16	Effect of Levothyroxine suppressive therapy on bone mineral density in patients with well-differentiated thyroid carcinoma	Dr. Faria Nasreen, et al (Bangladesh)
17	Thyroid cancer in Latvia: Review of statistical data and some management problems	Dr. Antra Bergina, et al. (Latvia)
18	Is Measuring of ¹³¹ I Thyroid Uptake Using Gamma Camera Reliable Enough?	Dr. Milovan Matovic, et al (Serbia)
19	Persistent and unusual combination of negative thyroglobulin levels and positive I-131 avid metastases in a patient with metastatic follicular carcinoma of thyroid	Dr. Butch Magsombol, et al (Singapore)
20	Clinical Significance of Serial Measurements of Serum Thyroglobulin & Thyroglobulin Antibodies In Differentiated Thyroid Cancer Patients	Dr. Shazia Fatima, et al. (Pakistan)
21	Radioiodine Treatment Complications in Mother and Child in Patients with Differentiated Thyroid Carcinoma	Dr. Abbas Takavar, et al. (Iran)
22	Evaluation of the efficacy of low and high dose radioiodine therapy for ablation	Dr. Abbas Takavar, et al. (Iran)

PROGRAMME (ICRT-2009)

23	Predictive value of TSH levels after 131-I treatment of patients with Grave's disease	Dr. Pavel Bochev (Bulgaria)
24	Diagnostic Value of Serum Thyroglobulin in Differentiated Thyroid Carcinoma Patients to Monitor Persistence or Recurrence Disease	Dr. Aisyah Elliyanti (Indonesia)
25	Umbilical cord blood TSH values in neonates for screening of congenital hypothyroidism	Dr. Ansari M.I.H, et al. (Bangladesh)
1015-1100	Networking, Posters & Coffee Break Poster Coordinators: Dr. Mohd. Aleem Khan, Dr. Nigora Rasulova ALL POSTERS FROM SCIENTIFIC SESSION-1 & 4 WILL BE VIEWED AND DISCUSSED	
1100-1300	Scientific Session-2 Thyroid:II Chairpersons: Dr. Omar Alonso (Uruguay), Dr. E. Barrenechea (Philippines)	
	Invited Lectures	
1100-1125	26 Radioiodine-negative, Somatostatin-Receptor PET-negative Thyroid Cancer: Current Status and Developments	Prof. Roy Moncayo (Austria)
1125-1150	27 Paediatric Thyroid Cancer	Prof. Isabel Roca (Spain)
1150-1215	28 rhTSH stimulated radioiodine therapy of metastatic differentiated thyroid cancer, an off-label use: Initial experience	Prof. C.S. Bal (India)
1215-1240	29 Radioiodine Therapy of Benign Thyroid Disorders	Prof. A. Klissarova (Bulgaria)
1240-1300	30 Targeted Radiotherapy and Radiobiology	Dr. Maria Neves (Portugal)
1300-1400	Lunch	
1400-1550	Scientific Session-3 Neuroendocrine Tumours-1 Chairpersons: , Dr. Savvs Frangos (Cyprus), Prof. G. Wiseman (USA)	
	Invited Lectures	
1400-1425	31 Chemical aspects of labelling octreotides	Dr. Mikolajczak Renata (Poland)
1425-1450	32 The Targeting of G-protein Coupled Receptors with Radiopeptides for Imaging and Internal Radionuclide Therapy.	Prof. H. R. Maecke (Switzerland)
1450-1520	33 An update on our experience with Peptide Receptor Radiotherapy (PRRT) in Neuroendocrine Tumours (NETs)	Prof. R. P. Baum (Germany)
1520-1550	34 Lanreotide-based Diagnosis and Treatment of Cancer Patients: Current Status, Indications, Future Directions.	Prof. Roy Moncayo (Austria)
1550-1610	Coffee Break	
1610-1800	Scientific Session-4 Neuroendocrine Tumours-2 Chairpersons: Prof. R. Moncayo (Austria), Dr. N. Watanabe (Japan)	
	Invited Lectures	
1610-1635	35 Concomitant chemotherapy, radioimmunotherapy of lymphoma and radiopeptide control of endocrine cancer.	Prof. J.H. Turner (Australia)

1635-1700	36	Bisphosphonates conjugated to macrocyclic ligands: ⁶⁸ Ga-based PET/CT imaging tracers vs. ¹⁷⁷ Lu-based therapy.	Prof. Dr. Frank Roesch (Germany)
1700-1720	37	Treatment of neuroendocrine tumors with radiolabeled peptide: The Chilean Experience Proffered Papers (Oral Presentations)	Prof. Horacio Amaral (Chile)
1720-1800		Oral Presentations	
	38	Survival benefits and efficacy of Peptide Receptor Radionuclide Therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in Pancreatic Neuroendocrine Tumors (pNET)	Prof. R. P. Baum, et al. (Germany)
	39	Comparison between clinical results of PRRT with ⁹⁰ Y-DOTA TATE and ⁹⁰ Y/ ¹⁷⁷ Lu- DOTATATE	Dr. Jolanta Kunikowska, et al (Poland)
	107	Evaluación de la terapia de tumores neuroendocrinos con análogos de somatostatina radio-marcados.	José Canessa, Teresa Massardo, Paz Arteaga, Juan Ilzauspe, Pedro Pineda (Chile)
	41	Tratamiento de tumores neuroendocrinos (tne) con péptidos análogos de la somatostatina marcados con radionucleidos (<i>Treatment of neuroendocrine tumors (TNE) with peptides of somatostatine labelled with radionuclides</i>)	Horacio Amaral, Rossana Pruzzo, Cecilia Gil, Irene Coudeu, Hugo Lavados, Francisca Redondo, Bárbara Morales (Chile)
Poster Presentation (To be viewed and discussed during the coffee break at 1015-11 am on (04/11/09))			
	42	Effectiveness of treatment of gastroenteropancreatic non-functioning neuroendocrine tumours consisted of Sandostatin LAR® after ⁹⁰ Y - and/or ¹⁷⁷ Lu - DOTA-TATE therapy.	Dr. Norbert Szalus, et al. (Poland)
	43	Peptide receptor radionuclide therapy in neuroendocrine tumors: preliminary results in 18 cases treated with ⁹⁰ Y-DOTATOC	Dr. Lutfun Nisa, et al (Bangladesh)
	44	Preparation of [¹⁸ F] containing neurotensine-derived peptides	Dr. Horvath Geza, et al (Denmark)
	45	I-131 MIBG Imaging in the Diagnosis of Pheochromocytoma: 'Philippine Setting'	Dr. Erik Cruz, et al. (Philippines)
1800-1900		WRPTC Members' Assembly	
All participants of ICRT-2009 and ALASBIMN Congress are defacto members of WRPTC and are welcome to attend this Assembly and contribute to the proceedings			
1900-2000		FREE TIME	
2000-2300		Oenophilous Dinner Hosted by World Nuclear Oenophilous Society	Venue: Cartagena Club http://clubcartagena.com
Thursday: 5 November 2009			
Scientific Session-5 (Plenary with ALASBIMN Congress) ALASBIMN Opening & Combined Plenary with ALASBIMN Chairpersons: , Prof. I. Mena (Chile), Prof. S. Goldsmith (USA)			
0800-0815		ALASBIMN Opening	Dr. Patricia Bernal (Colombia)

PROGRAMME (ICRT-2009)

0815-0850	46	Contribution of nuclear medicine in early breast cancer: from ROLL (Radioguided Occult Lesion Localization) to IART® (Intra-operative Avidination for Radionuclide Therapy	Prof. Giovanni Paganelli (Italy)
0850-0930	47	PET/CT in Lung Cancer and Oncology Guidelines - Has it Become a Must?	Prof. R. Baum (Germany)
0930-1000 Coffee Break			
1000-1200 Scientific Session-6 Radiosynovectomy & Bone Pain Palliation Chairpersons: Dr. S. Srivastava (USA), Prof. AH Elgazzar (Kuwait)			
Invited Lectures			
1000-1025	48	Radionuclide therapy of bleeding joints in Haemophilia: A review	Dr. E. Barrenechea (Philippines)
1025-1050	49	Radiosynoviorthesis (RSO): influencing factors and therapy monitoring	Dr. K. Liepe (Germany)
1050-1110	50	Treating bone metastases use of radionuclides in combination with other therapies	Dr. J. Buscombe (UK)
1110-1135	52	Metabolic Radionuclide Therapy of Metastatic Bone Pain Using ⁸⁹ SrCl (Metastron) - Review and Perspectives	Prof. A. Klissarova (Bulgaria)
Proffered Presentations			
1135-1200 Oral Presentation			
	53	Metabolic Radionuclide Therapy in Painful Bone Metastases with ⁸⁹ SrCl : Better Patients' Selection for Therapy	Dr. Zhivka Dancheva (Bulgaria)
	54	Knowing people, caring for persons, not just treating pain: 15 years delivering radionuclides to palliate bone pain.	Morales R, Cano R, Mendoza G (Peru)
	55	Radiosynoviolisis (rsnv) con Re188-coloide en sinovitis villonodular (svn) recidivante de rodilla. Experiencia clinico terapeutica (<i>Radiosynoviolisis (rsnv) with Re 188 colloid in synovitis villonodular (svn) recidivant of knee. Experience clinical and therapeutical</i>)	Alvaro Calderon, Augusto Llamas Olier, Humberto Varela, Amelia de los Reyes, Maria Cristina Martinez, Emperatriz Angarita, Nidia Delgado, Rada, César Villamil. Camilo Soto Javier Alejandro Estévez(Colombia)
	56	Estudio biocinético y dosimétrico de un kit de producción local de ¹⁷⁷ Lu-edtmp para su uso como agente paliativo del dolor. (<i>Biokinetic study and dosimetry evaluation of Lu-177 EDTMP for use in the palliative treatment of bone pain</i>)	Nancy Puerta Yepes, Juan Horacio Pérez, Noemí Nélica Nevares, Alfredo Miguel Zapata, Ana Clarisa López Bularte, Ana María Rojo, Sebastián Gossio, José Luis Crudo (Argentina)
Poster (To be viewed and discussed during the coffee break at 1200-1300 hrs. TO DAY (05/11/09))			
	57	¹⁵³ Sm-oxabiphore radionuclide therapy combined with external beam radiation therapy (8Gy) in breast cancer patients with bone metastases	Prof. Valeriy Krylov, et al. (Russia)
	58	Therapeutic Response of Radiosynovectomy with ³² P Colloid in Haemophilic Synovitis of Adolescents	Dr. Pei-yong LI (China, PR)
	59	Development of a New ¹³¹ I-Labelled	Dr. Alejandro Perera (Cuba)

60	Bisphosphonic Acid for Palliative Therapy of Metastatic Bone-Pain. Radionuclide Therapy in Patients with Painful Bone Metastases due to prostate Carcinoma. Efficacy of Strontium-89 Chloride	Dr. R. Mititelu (Romania)
61	Is radiosynoviorthesis of medium and small joints in patients with rheumatoid arthritis effective?	Dr. Otakar Kraft, et al. (Czech Republic)
62	Effect of combined Samarium-153 and adjuvant analgesic therapy for pain palliation in patients with skeletal metastases	Dr. S. Barai (India)
63	The duration of pain free period after Sm-153 EDTPM palliative treatment of skeletal bone MTS in patient moderate severity of bone pain in comparison to group of patient with severe to intolerable pain.	Dr. N. Rasulova (Uzbekistan)
64	Possibility of using Tc99m (V) DMSA in assessment to treatment response of patients with gastro intestinal stromal tumor.	Dr. Vladimir Lyubshin, et al. (Uzbekistan)
65	Bone pain from osteoblastic metastases	Dr. Fahid Ibrar, Dr. Baber Juniad (Pakistan)
1200-1300	Networking, Posters & Coffee Break Poster Session Coordinator: Dr. Shazia Fatima (Pakistan), Dr. Antra Berzeina (Latvia) ALL POSTERS FROM SCIENTIFIC SESSIONS-5, 6,7and 8 WILL BE VIEWED AND DISCUSSED	
1300-1400	Lunch	
1400-1630	Scientific Session-7 Liver Cancer & Miscellaneous Chairpersons: Prof. Azu Owunwanne (Kuwait), Prof. Keon Wook Kang (S. Korea)	
	Invited Lectures	
1400-1430	66 Statistics don't lie – do people?	Prof. J. Stare (Slovenia)
1430-1450	67 Recent advances in radioconjugate targeting	Prof. D.K. Hazra (India)
1450-1520	68 Targeted Liver Tumor Therapy with Radioembolization	Prof. G. Wiseman (USA)
1520-1550	69 A perspective on WRPTC: We may not change the world, but we can make a small difference	Prof. A.K. Padhy (Singapore)
1550-1615	51 Results of autoradiographic uptake of Re-188-HEDP	Dr. K. Liepe (Germany)
	Oral Presentations	
1615-1630	70 Evaluación de la eficacia terapéutica de un complejo mixto 188re(v)-oxo como potencial agente para terapia de melanoma (<i>Evaluation of the therapeutic efficacy of Re-188(V) - oxo like potential agent for melanoma therapy</i>)	S. Fernández, J. Giglio, M. Terán, M. Incerti, C. Agorio, A. Chabalgoity, A. Rey (Uruguay)
	40 Ensayos preclínicos del 177lu-dota-minigastrina para su potencial uso en prrt (Preclinical trial of Lu-177-dota-minigastrin for potential use in prrt)	López Bularte A.C, Puerta Yepes N, Nevares N, Zapata M, Rojo A.M, Crudo J (Argentina).
1630-1645	Coffee Break	

PROGRAMME (ICRT-2009)

1645-1815		Scientific Session-8 Radioimmunotherapy Chairpersons: Prof. Horacio Amaral (Chile), Prof. Kalevi Kairemo (Finland)	
Invited Lectures			
1645-1715	71	Radioimmunotherapy of Lymphoma	Prof. Stanley Goldsmith (USA)
1715-1745	72	Radioimmunoscintigraphy and Radioimmunotherapy: Summary of 20 years of experience and the state of the art".	Prof. I. Garty (Israel)
1745-1815	73	Radioimmunotherapy of Prostate Carcinoma	Prof. Stanley Goldsmith (USA)
Poster Presentations (To be viewed and discussed during the poster session at 1200-1300 hrs. TO DAY (05/11/09))			
	74	Development of ¹⁷⁷ Lu- Dendrimer-Anti-CD20 : preliminary studies	Dr. Marcos Tassano, et al. (Uruguay)
	75	Development of ¹⁵³ Sm-DTPA-Rituximab for radioimmunotherapy	Dr. Amir R Jalilian, et al (Iran)
	76	¹⁷⁷ -Lu-Anti-CD20 monoclonal antibody: A potential radiopharmaceutical for treatment of non-Hodgkin's lymphoma	Dr. Paola Audicio, et al (Uruguay)
	77	Sterically stabilized ¹⁷⁷ Lu de DTPA-Liposomes and ¹⁷⁷ Lu DTPA-Liposomes: development of labeling procedure and biologic evaluation	Dr. Mirel Cabrera, et al. (Uruguay)
	78	¹⁷⁷ Lu –Bevacizumab: a novel therapeutic radiopharmaceutical	Dr. Ximena Camacho, et al (Uruguay)
	79	In vivo characterization of a Lu-177 Bombesin- based radiopharmaceutical for GRP Positive tumours - Diagnosis & Treatment	Dr. Priscilla Brunelli Pujatti, et al. (Brazil)
	80	¹⁷⁷ Lu-DOTA-TATE and Sandostatin LAR as a promising therapy of Esthesioneuroblastoma- case report	Dr. Zbigniew Podgajny, et al (Poland)
	81	¹⁷⁷ Lu - Dendrimer PAMAM G4: Evaluation in a murine melanoma model	Dr. Marcos Tassano, et al. (Uruguay)
1915-2300		Reception and Dinner Formal ceremony at TEATRO ADOLFO MEJIA (19.15-20.30) Cocktail - Dinner at PLAZA DE LA MERCED (21.00-23.00)	
Friday: 6 November 2009			
0900-1700		Sight-seeing tour with Lunch (Details are being worked out)	
1930		Dinner at Hilton	
Saturday: 7 November 2009			
0830-1100		Scientific Session - 9 Molecular Imaging in Therapy Chairpersons: Dr. Isabel Roca (Spain), Prof. D.K. Hazra (India)	
Invited Lectures			
0830-0900	82	Road Map to Molecular Imaging: Historic and Basic Considerations	Prof. AH Elgazzar (Kuwait)
0900-0930	83	PET/CT and Radiotherapy Planning	Dr. Subramaniam Rathan (USA)
0930-1000	84	The Importance of Quantitative Molecular Imaging: From MORE (Molecular Response) to	Prof. R. Baum (Germany)

1000-1030	85	PERCIST (PET Response Criteria in Solid Tumors) Use of PET/CT imaging with ⁶⁸ Ga DOTATATE in the evaluation of patients with neuroendocrine tumors Proffered Papers	Dr. Horacio Amaral (Chile)
Poster Presentations: (To be viewed and discussed during the coffee break at 1030-1100 hrs on (07/11/09))			
	88	Effects of external beam irradiation on Radioimmunotargetting	Dr. Padmamalika Khanna-Hazra, et al (India)
	89	Rapid guide for drug interaction with radiopharmaceutical	Ralph Santos-Oliveira, et al (Brazil)
	90	Targeted imaging with ⁶⁴ Cu trastuzumab PET in non small cell lung cancer	Dr. Bishnuhari Paudyal, et al. (Japan)
	91	Evaluation of risk of increased cerebral blood flow by intravenous adenosine-tri-phosphate: A PET study with ¹⁵ O-labeled water.	Dr. Raihan Hussain (Bangladesh)
	92	Phase I Clinical Trial and Pharmacokinetics of the anti-CEA single chains fragment (scFv) ₂ M3	Dr. Gilmara Pimentel, et al (Cuba)
	93	Experience of Radiopharmaceutical Therapy in a Developing Country	Dr. Hasan Mizanul, et al (Bangladesh)
1030-1100	Networking, Posters & Coffee Break Poster Session Coordinator: Dr. R Mititelu (Romania), Dr. Ana Ugrinska (Macedonia) ALL POSTERS FROM SCIENTIFIC SESSIONS-9 and 10 WILL BE VIEWED AND DISCUSSED		
1100-1300	Scientific Session - 10 Miscellaneous Chairpersons: Dr. J. Buscombe (UK), Prof. H. R. Maecke (Switzerland)		
	Invited Lectures		
1100-1130	94	Molecular Radiotherapy for Human Neuroblastoma Cells with Auger Electrons of In- ¹¹¹ -labeled N-myc Antisense Oligonucleotides in Combination with Chemotherapy	Dr. N. Watanabe (Japan)
1130-1200	86	The limitations of CT to monitor radionuclide therapy in Neuro-endocrine tumours	Dr. John Buscombe (UK)
1200-1230	87	In the current world of PET/CT for therapeutic monitoring, who needs Tc- ^{99m} and the other non-positron emitting radiopharmaceuticals?	Prof. Azu Owunwanne (Kuwait)
1230-1300	96	PBPK modeling for dosimetry of nonclinical and clinical radioimmunotherapy Proffered Papers	Prof. Kalevi Kairemo (Finland)
Posters (To be viewed and discussed during the coffee break at 1030-1100 hrs. TO DAY (07/11/09))			
	97	Architecture & Music in the Light of Healing of Cancer Patients	Dr. Gertraud Jestl-Horngache (Austria)
	98	Primary Tumor Size, Can It Predict the Histopathologic Outcome of an Identified	Dr. Susan Gironella-Camomot, et al (Philippines)

PROGRAMME (ICRT-2009)

99	Sentinel Node? Evaluation of sentinel lymph nodes in patients with cutaneous malignant melanoma	Dr. M. Lacic (Croatia)
100	SPECT imaging in the diagnosis of pulmonary embolism, comparison with planar V/Q scan and CTPA	Dr. Fatima Shazia, et al (Pakistan)
101	Evaluation of Performance of Rest Gated Myocardial Perfusion Imaging in Emergency Room Patients with Suspected Acute Coronary Syndrome presenting with Acute Chest Pain and Non-diagnostic ECG - Preliminary results from the PREMIER tria	Dr. Arzoo Fatima (Pakistan)
102	Myocardial infarction, scar or ischemia at rest?	Maruf Pirnazarov (Uzbekistan)
103	Carcinoma of Unknown Primary: Initial Experience with 18F FDG PET-CT	Madhur Kumar Srivastava (India)
104	Prediction of response to neoadjuvant chemotherapy in locally advanced breast cancer with scintimammography and its correlation with p-glycoprotein levels	Dr. Muhammad Aleem Khan (Pakistan)
1300-1400	Lunch	
1400-1600	Scientific Session - 11 Closing Session Chairpersons: Prof. Richard P. Baum (Germany), Dr. Patricia Bernal (Colombia)	
	Invited Lectures	
1400-1425	105 Alpha therapies present practice and future prospects	Dr. John Buscombe (UK)
1425-1450	106 Our Experience Comparing Bi-213 with Lu-177 in a prostate cancer model.	Prof. H. R. Maecke (Switzerland)
1450-1600	Inauguration of WARMTH Introduction to ICRT-2010 (Bali): Address by the Organizing Chairman Introduction to ICRT-2012 (Finland) Address by the Organizing Chairman Closing Remarks	Dr. Hussein Kartamihardja (Indonesia) Prof. K. Kairemo (Finland)
	Highlights and closing remarks	Dr. Patricia Bernal, Chairperson - Organizing Committee (ICRT-2009) A.K. Padhy (Singapore)
1600-1630	Coffee Break	
1630-2000	FREE TIME A few interesting Scientific Sessions of ALASBIMN will still be continuing in other Lecture Halls. Those who are interested may attend and participate in them also (Please refer to the ALASBIMN Programme).	
2000-onwards	Closing Ceremony of ICRT-ALASBIMN Congress Dinner Latin Music & Dance and Celebrations	

DRESS CODE FOR CLOSING CEREMONY : ALL WHITE